Background <p>Accurate mediastinal staging is essential for treatment planning and prognostic assessment in patients with extrapulmonary malignancies. Endobronchial ultrasonography (EBUS) has emerged as a minimally invasive modality for mediastinal evaluation; however, evidence regarding its diagnostic performance in extrapulmonary malignancies remains limited.</p> Methods <p>Patients with known extrapulmonary malignancies who underwent EBUS for mediastinal staging were retrospectively analyzed. Demographic characteristics, radiological findings, sampled lymph node stations, and pathological results were evaluated. Factors potentially associated with malignant mediastinal involvement were assessed.</p> Results <p>EBUS enabled successful sampling of mediastinal and hilar lymph nodes across multiple stations. Malignant involvement was identified in a subset of patients, while benign etiologies—including reactive and granulomatous lymphadenopathy—accounted for the majority of cases. Increased lymph node diameter was associated with malignancy, whereas primary tumor type and the number of sampled lymph nodes were not independent predictors of malignant pathology.</p> Conclusions <p>EBUS appears to be a safe and reliable tool for mediastinal staging in patients with extrapulmonary malignancies. Its minimally invasive nature and diagnostic performance support its use as a first-line modality, potentially reducing the need for confirmatory mediastinoscopy in selected patients.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Di̇agnosti̇c yi̇eld of EBUS i̇n medi̇asti̇nal stagi̇ng of extrapulmonary mali̇gnanci̇es; si̇ngle center cli̇ni̇cal experi̇ence

  • Mehmet Akif Ekici,
  • Oguzhan Turan,
  • Enes Fatih Çelik,
  • Mehmet Akif Tezcan,
  • İbrahim Ethem Özsoy,
  • Bayram Metin

摘要

Background

Accurate mediastinal staging is essential for treatment planning and prognostic assessment in patients with extrapulmonary malignancies. Endobronchial ultrasonography (EBUS) has emerged as a minimally invasive modality for mediastinal evaluation; however, evidence regarding its diagnostic performance in extrapulmonary malignancies remains limited.

Methods

Patients with known extrapulmonary malignancies who underwent EBUS for mediastinal staging were retrospectively analyzed. Demographic characteristics, radiological findings, sampled lymph node stations, and pathological results were evaluated. Factors potentially associated with malignant mediastinal involvement were assessed.

Results

EBUS enabled successful sampling of mediastinal and hilar lymph nodes across multiple stations. Malignant involvement was identified in a subset of patients, while benign etiologies—including reactive and granulomatous lymphadenopathy—accounted for the majority of cases. Increased lymph node diameter was associated with malignancy, whereas primary tumor type and the number of sampled lymph nodes were not independent predictors of malignant pathology.

Conclusions

EBUS appears to be a safe and reliable tool for mediastinal staging in patients with extrapulmonary malignancies. Its minimally invasive nature and diagnostic performance support its use as a first-line modality, potentially reducing the need for confirmatory mediastinoscopy in selected patients.